REACHing forward-a strategic vision for ECCO and the future of IBD care [0.03%]
展望未来——制定欧洲克罗恩病和结肠病组织(REACH)战略计划及IBD诊疗愿景
Britta Siegmund,Ailsa Hart
Britta Siegmund
Tunnel vision: Rethinking local therapy for perianal fistulas in Crohn's disease [0.03%]
隧道视野：对克罗恩病并会阴部脓肿的局部治疗的新思考
Maria Manuela Estevinho,Eathar Shakweh,WonKyung Cho et al.
Maria Manuela Estevinho et al.
Background and aims: Local therapies involving direct delivery of agents to fistula tracts in perianal fistulizing Crohn's disease (PFCD) have been explored but are not standard in clinical practice. We aimed to conduct a...
Cutaneous autoimmune blistering disease during mirikizumab therapy in a patient with ulcerative colitis: a new potential trigger? [0.03%]
溃疡性结肠炎患者在使用米里基朱玛治疗期间出现皮肤自身免疫性水疱病：一个新的潜在触发因素？
Lucia Centanni,Fabrizio Fanizzi,Ferdinando D&#x;amico et al.
Lucia Centanni et al.
Autoimmune blistering diseases (AIBDs) may occur as adverse effects of various therapies, including biologics. Data on their association with IL-23 inhibitors in ulcerative colitis (UC) remain limited. We report the case of a 59-year-old ma...
Beyond the mucosa: intestinal ultrasound for post-endoscopic healing risk stratification in ulcerative colitis [0.03%]
黏膜以外：肠超声在溃疡性结肠炎内镜愈合风险分层中的作用
Shintaro Sagami,Katsuyoshi Matsuoka,Taku Kobayashi
Shintaro Sagami
Correction to: Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis [0.03%]
瑞沙珠单抗治疗中至重度活动性溃疡性结肠炎疗效和安全性的糖皮质激素节省效应的校正说明
Published Erratum
Journal of Crohn's & colitis. 2026 Feb 5;20(2):jjag002. DOI:10.1093/ecco-jcc/jjag002 2026
A Descriptive Comparison of Phase 3 Results and Head-to-Head Trials in Inflammatory Bowel Diseases [0.03%]
描述性比较炎症性肠病三期结果及直接对照试验
Zlata Chkolnaia,Laurent Peyrin-Biroulet,Mathieu Uzzan
Zlata Chkolnaia
Background: With the increasing number of effective therapies for inflammatory bowel diseases (IBD), determining optimal treatment sequences is challenging. Given the impracticality of conducting randomized head-to-head t...
Mechanistic insights into FMT for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial [0.03%]
粪菌移植治疗溃疡性结肠炎的机制研究：STOP-Colitis试验分析
Mohammed Nabil Quraishi,Catherine A Moakes,Mehmet Yalchin et al.
Mohammed Nabil Quraishi et al.
Background and aims: Faecal microbiota transplantation (FMT) is a promising therapy for ulcerative colitis, but variable responses and unclear mechanisms limit its efficacy. We aimed to compare nasogastric versus colonic ...
Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD services [0.03%]
基于英国炎症性肠病基准数据（超过26000名成人患者和154个IBD服务）的炎症性肠病患者和服务报告的质量护理比较分析（2019年与2023年）
A Barney Hawthorne,Paul Christiansen,Ian Arnott et al.
A Barney Hawthorne et al.
Introduction: The IBD U.K. Benchmarking surveys, conducted in 2019 and 2023 collected repeated data regarding the quality of inflammatory bowel disease (IBD) care across the U.K. using both service self-assessments and pa...
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib [0.03%]
弗立加替尼治疗溃疡性结肠炎患者黏膜转录组特征与内镜组织学结果相关性分析
Fernando Magro,Gerhard Rogler,Brian G Feagan et al.
Fernando Magro et al.
Background: Filgotinib, a Janus kinase 1-preferential inhibitor, is approved for the treatment of moderately to severely active ulcerative colitis (UC). A...
From oncology to IBD: HLA pharmacogenetics informs combination immunotherapy to prevent treatment failure [0.03%]
从肿瘤学至炎症性肠病：HLA药物基因组学告知免疫组合疗法以防止治疗失败
Longjun Huang,Yanquan Zhou
Longjun Huang